Dexcom (DXCM) EBIT (2010 - 2026)

Dexcom (DXCM) has 17 years of EBIT data on file, last reported at $255.3 million in Q1 2026.

• EBIT for Q1 2026 came in at $255.3 million, up 90.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 63.36% YoY), and the FY2025 annual result was $911.8 million, up 51.97% from the prior year.
• EBIT slipped to $255.3 million in Q1 2026 per DXCM's latest filing, from $323.0 million in the prior quarter.
• Over five years, EBIT peaked at $323.0 million in Q4 2025 and troughed at $41.3 million in Q1 2022.
• A 5-year average of $162.1 million and a median of $152.0 million in 2024 frame the typical range for EBIT.
• The sharpest annual moves came in 2022 and 2024: EBIT surged 20800.0% in 2022, then slipped 26.03% in 2024.
• A 5-year view of EBIT shows it stood at $125.4 million in 2022, then soared by 72.97% to $216.9 million in 2023, then declined by 12.91% to $188.9 million in 2024, then jumped by 70.99% to $323.0 million in 2025, then retreated by 20.96% to $255.3 million in 2026.
• Business Quant data shows DXCM's EBIT at $255.3 million in Q1 2026, $323.0 million in Q4 2025, and $242.5 million in Q3 2025.